Form 4: 10x Genomics CEO Serge Saxonov Transfers Shares to Trusts
SEC Form 4 Filing
Serge Saxonov, CEO of 10x Genomics, reports the transfer of Class A Common Stock to various trusts in a recent SEC filing.
Summary
- Serge Saxonov, the CEO of 10x Genomics, filed a Form 4 with the SEC.
- The filing reports changes in his beneficial ownership of 10x Genomics Class A Common Stock.
- On March 14, 2024, Saxonov transferred 29,900 shares to the Y/S Descendants' Trust and 6,250 shares to the Y/S Pot Trust.
- Following the transaction, Saxonov directly owns 805,664 shares.
- He also indirectly owns shares through several trusts where he serves as trustee: the Andromeda Trust (27 shares), the Sirius Trust (870 shares), the Y/S Descendants' Trust (213,250 shares), and the Y/S Pot Trust (22,570 shares).
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a transfer of shares to trusts, which is neutral in sentiment.
Industry Context
This filing is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's overall prospects or strategy. It is common for executives to manage their personal holdings through trusts for estate planning purposes.
Stakeholder Impact
- The transfer of shares to trusts has no immediate impact on shareholders, employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of the stock transfer to the Y/S Descendants' Trust and Y/S Pot Trust |
| 03/18/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.